Xolair: New England Journal of Medicine publishes Phase III data showing Xolair significantly reduced allergic reactions across multiple foods in people with food allergies

(marketscreener.com) Detailed results from the NIH-sponsored Phase III OUtMATCH study showed treatment with Xolair increased the amount of peanuts, tree nuts, egg, milk and wheat that people as young as 1 year consumed without an allergic reaction The U.S. FDA recently approved Xolair as the first and only medicine for children and adults with one or more food...https://www.marketscreener.com/quote/stock/ROCHE-HOLDING-AG-149358831/news/New-England-Journal-of-Medicine-publishes-Phase-III-data-showing-Xolair-significantly-reduced-allerg-46025064/?utm_medium=RSS&utm_content=20240225